Trials / Withdrawn
WithdrawnNCT00719823
Maraviroc Compassionate Use
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to provide Maraviroc on a compassionate use basis to antiretroviral treatment experienced patients infected with CCR5-tropic HIV-1 with urgent unmet medical needs and who, in the opinion of the physician, require Maraviroc to form a viable regimen.
Detailed description
This study was cancelled prior to enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maraviroc | Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2008-07-22
- Last updated
- 2016-05-04
Source: ClinicalTrials.gov record NCT00719823. Inclusion in this directory is not an endorsement.